natgillin/translations-raw huggingface dataset:
A mass balance study showed that approximately 57% of radiolabelled olanzapine appeared in urine, principally as metabolites.
Pri glodavcih so se po peroralnem dajanju pojavili znaki toksičnosti, znač za moč antipsihotič
82 In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/ hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/ hr, respectively).
ilni
The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus males, and in non-smokers versus smokers.
ne
In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.
spojine: hipoaktivnost, koma, tresenje, klonič krč slinjenje in zmanjš pridobivanje telesne mase.
1
ni
Paediatric population Adolescents (ages 13 to 17 years):
i,
5.3 Preclinical safety data
ano
Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found.
odmerka odvisno zmanjš koncentracije levkocitov v krvi pri miš in nespecifič zmanjš
Reversible neutropenia, thrombocytopenia, or anemia developed in a few dogs treated with 8 or 10 mg/ kg/ day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Pri nekaj psih, ki so jim dajali 8 ali 10 mg/ kg na dan (celotna izpostavljenost olanzapinu je bila 12 - do 15- krat več kot pri č
In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow.
loveku, ki dobi 12- miligramski odmerek), se je razvila reverzibilna
Reproductive toxicity Olanzapine had no teratogenic effects.
Vpliv na sposobnost razmnož evanja Olanzapin ni povzroč teratogenih uč
Sedation affected mating performance of male rats.
Sedacija je vplivala na uspeš parjenja podganjih nost
Estrous cycles were affected at doses of 1.1 mg/ kg (3 times the maximum human dose) and reproduction parameters were influenced in rats given 3 mg/ kg (9 times the maximum human dose).
loveka) so vplivali na estrusne cikle,
In the offspring of rats given olanzapine, delays in fetal development and transient decreases in offspring activity levels were seen.
Pri potomcih podgan, ki so dobivale olanzapin, so opazili zastoje v razvoju zarodka in prehodna zmanjš aktivnost potomcev. ana
83 Mutagenicity Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
Mutagenost Standardni testi, med katerimi so bili tudi testi mutiranja bakterij ter testi in vitro in in vivo na sesalcih, niso potrdili mutagenosti in klastogenosti olanzapina.
8.
70 Š 8.
85 1.
71 1.
Zalasta 5 mg orodispersible tablets
Zalasta 20 mg tablete
Each orodispersible tablet contains 5 mg olanzapine.
1 tableta vsebuje 20 mg olanzapina.
Each orodispersible tablet contains 0.50 mg aspartame.
Pomož snov: na 1 tableta vsebuje 323, 5 mg laktoze.
Tablets are round, slightly biconvex, yellow marbled tablets with possible individual spots.
Tablete so okrogle, rahlo izboč svetlo rumene barve z morebitnimi posameznimi rumenimi pikami ene, in napisom 20.
During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5- 20 mg/ day.
72 Med zdravljenjem shizofrenije in manič epizode in med prepreč
86 Olanzapine can be given without regards for meals as absorption is not affected by food.
enega začetnega odmerka priporoč le po ponovni klinič amo
Gradual tapering of the dose should be considered when discontinuing olanzapine.
Pred ponovnim poveč anjem odmerka mora miniti najmanj 24 ur.
Zalasta orodispersible tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed.
Bolniki lahko jemljejo olanzapin ne glede na obroke, ker hrana ne vpliva na absorpcijo.
Removal of the intact orodispersible tablet from the mouth is difficult.
Med ukinjanjem olanzapina je treba odmerek zmanjš evati postopno.
Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister.
Otroci in mladostniki Zaradi pomanjkanja podatkov o varnosti in uč
Alternatively, it may be dispersed in a full glass of water immediately before administration.
inkovitosti olanzapina ne priporoč za uporabo pri amo
Olanzapine orodispersible tablet is bioequivalent to olanzapine tablets, with a similar rate and extent of absorption.
otrocih in mladostnikih, mlajš od 18 let.
It has the same dosage and frequency of administration as olanzapine tablets.
V kratkotrajnih raziskavah na bolnih mladostnikih so ih poroč o več poveč telesne mase in o spremenjenih vrednostih lipidov in prolaktina kot v
Olanzapine orodispersible tablets may be used as an alternative to olanzapine tablets.
raziskavah na bolnih odraslih (gl. poglavja 4. 4, 4. 8, 5. 1 in 5. 2).
A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short term studies of adolescent patients than in studies of adult patients (see sections 4.4, 4.8, 5.1 and 5.2).
etnim odmerkom (5 mg na dan) zdravite bolnike, stare več 65 let, kadar to kot
Elderly A lower starting dose (5 mg/ day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see also section 4.4).
opravičujejo klinič dejavniki (gl. tudi poglavje 4. 4). ni
When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consider ation should be given to decreasing the starting dose.
Č je prisoten več en dejavnik, ki bi lahko prispeval k poč
In cases where dose increments of 2.5 mg are considered necessary, Zalasta tablets should be used.
Pri poveč
(See sections 4.5 and 5.2.)
etni
In placebo-controlled clinical trials (6-12 weeks
anjih, kontroliranih s placebom (ki so trajali 6 do 12
87 duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/ or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs.
tednov), pri starejš bolnikih s psihozo, povezano z demenco, in/ ali vedenjskimi motnjami ih (povpreč starost 78 let), je bilo 2- krat več
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs.
73 smrtnost, neodvisno od omenjenih dejavnikov tveganja, več pri bolnikih, zdravljenih z olanzapinom, ja kot pri bolnikih, zdravljenih s placebom.
In these trials, patients wer e initially required to be stable on the lowest effective dose of anti- Parkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian medicinal products and dosages throughout the study.
Zač odmerek olanzapina je bil 2, 5 mg na dan, nato pa so ga na podlagi presoje etni preiskovalca postopoma poveč
Additi onal signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Č se pri bolniku pojavijo znaki in simptomi, ki kaž na
88 Hepatic function Transient, asymptomatic elevations of hepatic transaminases, ALT, AST have been seen commonly, especially in early treatment.
aminotransferaze – ALT, aspartatne aminotransferaze – AST), posebno na zač zdravljenja.
Neutropenia Caution should be exercised in patients with low leukocyte and/ or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/ toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.
Previdnost je prav tako potrebna pri bolnikih, ki so imeli v preteklosti tež zaradi ave zavrtega delovanja kostnega mozga, ki so ga povzroč zdravila, toksič za kostni mozeg, pri
89 Postural hypotension Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials.
anjih z olanzapinom so pri starejš bolnikih redko poroč o posturalni ih ali
Aspartame Zalasta orodispersible tablets contain aspartame, a source of phenylalanine.
Laktoza Zalasta vsebuje laktozo.
May be harmful for people with phenylketonuria.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjš ane aktivnosti laktaze ali malabsorpcijo glukoze/ galaktoze ne smejo jemati tega zdravila.
90 Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.
Terapevtsko spremljanje plazemskih koncentracij valproata ni pokazalo, da bi bilo treba po uvedbi sočasnega zdravljenja z olanzapinom prilagoditi odmerek valproata.
QTc interval Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
76 Interval QTc Č predpisujemo olanzapin soč e asno z zdravili, za katera je znano, da podaljš ujejo interval QTc, je potreba previdnost (gl. poglavje 4. 4).
Spontaneous reports have been ver y rarely received on tremor, hypertonia, lethargy and sleepiness, in infants born to mothers who had used olanzapine during the 3rd trimester.
Zelo redko so poroč o tresenju, hipertoniji, letargiji in zaspanosti pri dojenč rojenih materam, ki
Adults The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appet ite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases (see section 4.4), rash, asthenia, fatigue and oedema.
poveč telesne mase, eozinofilija, zviš vrednosti prolaktina, holesterola, glukoze in trigliceridov
Thrombocytopenia Allergic reaction
obč asno povezane s ketoacidozo ali komo,
91 Metabolism and nutrition disorders Weight gain1
trigliceridov 2, 5 glikozurija poveč apetit
Dizziness Akathisia6
77 Bolezni ž evja ivč zaspanost
6
omotica
Parkinsonism 6
akatizija6
seizures or risk factors
jih je več bolnikov ina ž imela ali pa je o njih
Dyskinesia
parkinsonizem6 diskinezije6
for seizures were reported Neuroleptic malignant syndrome (see section 4.4) Dystonia (including oculogyration) Tardive dyskinesia Discontinuation symptoms7
e poroč ala nevroleptič maligni ni sindrom (gl. poglavje 4. 4) distonija (vključ z no okulogiracijo) tardivne diskinezije odtegnitveni simptomi7
Photosensitivity reaction Alopecia
visoka raven kreatin
Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary hesitation Reproductive system and breast disorders
zviš raven alkalne ana
92 Priapism General disorders and administration site conditions Asthenia Fatigue Oedema Investigations Elevated plasma prolactin levels 8 1
koncentracije prolaktina 8
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
78 č 1 Klinič pomembno poveč telesne mase so opazili pri vseh izhodišnih indeksih telesne mase
93 In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
valproatom in olanzapinom povzroč nevtropenije pri 4, 1% bolnikov; mož vzroč dejavnik so
Children and adolescents Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.
Posebnih klinič
Very common (≥ 10%), common (≥ 1% and < 10%).
izpostavljenosti (najmanj 24 tednov) več kot pri kratkotrajni. ja
Metabolism and nutrition disorders Very common:
Neželeni uč so navedeni po padajočresnosti, njihova pogostost pa je definirana z opisoma zelo
Weight gain9, elevated triglyceride levels10, increased appetite.
pogosti (≥10%) in pogosti (≥1% in < 10%).
Common:
Tabela 2.
Elevated cholesterol levels11 Nervous system disorders Very common:
Presnovne in prehranske motnje zelo pogosti: poveč telesne mase9, zviš ravni trigliceridov10, poveč apetit pogosti: zviš ravni ane Bolezni ž evja ivč
94 Signs and symptoms Very common symptoms in overdose (> 10% incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Znaki in simptomi Zelo pogosti simptomi pri prevelikem odmerjanju (incidenca > 10%) vključ ujejo tahikardijo, vznemirjenost/ nasilnost, dizartrijo, različ ekstrapiramidne simptome in motnje zavesti v razponu od ne sedacije do kome.
Management of overdose There is no specific antidote for olanzapine.
ivetju po akutnem prevelikem odmerjanju z odmerkom 1500 mg.
95 In a multinationational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p=0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).
V dvojno slepi primerjalni raziskavi shizofrenije ter shizoafektivnih in sorodnih motenj, v kateri je sodelovalo več av in skupaj 1481 bolnikov z različ
In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.
V raziskavi, v kateri so vsaj dva tedna spremljali soč asno zdravljenje bolnikov z litijem ali valproatom, je dodatek 10 mg olanzapina bolj zmanjš jakost simptomov manije po 6 tednih kot pri monoterapiji z litijem ali al valproatom.
Olanzapine orodispersible tablet is bioequivalent to olanzapine tablets, with a similar rate and extent of absorption.
Hrana na absorpcijo ne vpliva.
Olanzapine orodispersible tablets may be used as an alternative to olanzapine tablets.
Absolutna peroralna biološ uporabnost glede na ka intravensko dajanje ni bila določ ena.
Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours.
V jetrih se presnavlja s konjugacijo in oksidacijo.
The absorption is not affected by food.
V krvi je glavni presnovek 10- N- glukuronid, ki ne prehaja skozi krvnomož
Absolute oral bioavailability relative to intravenous administration has not been determined.
Citokroma P450 CYP1A2 in P450 CYP2D6 prispevata k
Olanzapine is metabolized in the liver by conjugative and oxidative pathways.
V raziskavah na ž
The major circulating metabolite is the 1 0-N-glucuronide, which does not pass the blood brain barrier.
ivalih so bili presnovki in
Cytochromes P450- CYP 1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Prevladujoč farmakološ aktivnost
96 In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/ hr).
Pri zdravih starejš osebah (65 let in več je bil v primerjavi z mlajš osebami srednji razpolovni
In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/ hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/ hr, respectively).
V primerjavi med kadilci in nekadilci (moš in ž kimi nekadilcih podaljš (38, 6 v primerjavi s 30, 4 ure),
97 Haematologic toxicity:
Hematološ toksič
Mutagenicity Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
Mutagenost Standardni testi, med katerimi so bili tudi testi mutiranja bakterij ter testi in vitro in in vivo na sesalcih, niso potrdili mutagenosti in klastogenosti olanzapina.
Mannitol Microcrystalline cellulose Crospovidone Low-substituted hydroxypropylcellulose Aspartame Calcium silicate Magnesium stearate
laktoza monohidrat upraš celuloza ena predgelirani koruzni škrob koruzni škrob brezvodni koloidni silicijev dioksid magnezijev stearat
Zalasta orodispersible tablets are available in boxes of 14, 28, 35, 56 or 70 tablets in blister packs (Al/ OPA/ Al/ PVC).
14, 28, 35, 56 ali 70 tablet, v š katli.
8.
84 Š 8.
Zalasta 7.5 mg orodispersible tablets
Zalasta 5 mg orodisperzibilne tablete
Each orodispersible tablet contains 7.5 mg olanzapine.
1 orodisperzibilna tableta vsebuje 5 mg olanzapina.
Each orodispersible tablet contains 0.75 mg aspartame.
Pomož snov: na 1 orodisperzibilna tableta vsebuje 0, 50 mg aspartama.
Tablets are round, slightly biconvex, yellow marbled tablets with possible individual spots.
Tablete so okrogle, rahlo izboč rumene barve z morebitnimi posameznimi rumenimi pikami. ene,
During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5- 20 mg/ day.
Med zdravljenjem shizofrenije in manič epizode in med prepreč
100 Olanzapine can be given without regards for meals as absorption is not affected by food.
86 Bolniki lahko jemljejo olanzapin ne glede na obroke, ker hrana ne vpliva na absorpcijo.
Gradual tapering of the dose should be considered when discontinuing olanzapine.
Ker se v slini hitro razpusti, jo je mogoč
Zalasta orodispersible tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed.
Ker je krhka, jo je treba dati v
Removal of the intact orodispersible tablet from the mouth is difficult.
usta takoj, ko bolnik odpre pretisni omot.
Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister.
Lahko pa jo neposredno pred zauž itjem razpusti v kozarcu, polnem vode ali druge ustrezne pijač (npr. pomaranč
Alternatively, it may be dispersed in a full glass of water immediately before administration.
nega soka, jabolčnega soka, mleka ali kave).
(See sections 4.5 and 5.2.)
evanju odmerka, kadar je to
4.3 Contraindications
indicirano, bodite pri takih bolnikih previdni.
Hypersensitivity to the active substance or to any of the excipients.
Bolnikom, ki jim boste odmerek poveč evali po 2, 5 mg, predpiš tablete Zalasta. ite
During antipsychotic treatment, improvement in the patient's clinical condition may take severa l days to some weeks.
Med zdravljenjem z antipsihotiki je treba bolnike skrbno opazovati.
101 duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/ or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs.
tednov), pri starejš bolnikih s psihozo, povezano z demenco, in/ ali vedenjskimi motnjami ih
1.5%, respectively).
87 (povpreč starost 78 let), je bilo 2- krat več
However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors.
iranjem, sedacija, nezadostna prehrana ali dehidracija, pljuč na
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs.
smrtnost, neodvisno od omenjenih dejavnikov tveganja, več pri bolnikih, zdravljenih z olanzapinom, ja kot pri bolnikih, zdravljenih s placebom.
However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and relat ed conditions.
sočasnimi drugimi boleznimi malo, svetujemo previdnost pri predpisovanju zdravila bolnikom s hipertrofijo prostate ali s paralitič ileusom ter z njim povezanimi stanji. nim
102 Hepatic function Transient, asymptomatic elevations of hepatic transaminases, ALT, AST have been seen commonly, especially in early treatment.
aminotransferaze – ALT, aspartatne aminotransferaze – AST), posebno na zač zdravljenja.
Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).
Ob soč olanzapina in valproata so pogosto poroč o nevtropeniji (gl. poglavje 4. 8). ali Prekinitev zdravljenja
Discontinuation of treatment Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported very rarely (< 0.01%) when olanzapine is stopped abruptly.
Zelo redko (< 0, 01%) so pri nenadni prekinitvi zdravljenja z olanzapinom poroč o akutnih ali simptomih, kot so znojenje, nespeč
103 Postural hypotension Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials.
anjih z olanzapinom so pri starejš bolnikih redko poroč o posturalni ih ali
Use in children and adolescents under 18 years of age Olanzapine is not indicated for use in the treatment of children and adolescents.
Uporaba pri otrocih in mladostniki, h mlajš od 18 let ih Olanzapin ni indiciran za zdravljenje otrok in mladostnikov.
Aspartame Zalasta orodispersible tablets contain aspartame, a source of phenylalanine.
Fenilalanin Zdravilo Zalasta vsebuje aspartam, ki vsebuje vir fenilalanina.
May be harmful for people with phenylketonuria.
Lahko š koduje ljudem s fenilketonurijo.
104 Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.
Terapevtsko spremljanje plazemskih koncentracij valproata ni pokazalo, da bi bilo treba po uvedbi sočasnega zdravljenja z olanzapinom prilagoditi odmerek valproata.
The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson's disease and dementia is not recommended (see section 4.4).
Pri bolnikih s Parkinsonovo boleznijo in demenco ni priporoč soč eno asno jemanje olanzapina in antiparkinsonskih zdravil (gl. poglavje 4. 4).
QTc interval Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
Interval QTc Č predpisujemo olanzapin soč e asno z zdravili, za katera je znano, da podaljš ujejo interval QTc, je potreba previdnost (gl. poglavje 4. 4).
Eosinophilia
zviš vrednosti ane
105 Metabolism and nutrition disorders Weight gain1
trigliceridov 2, 5 glikozurija poveč apetit
Dizziness Akathisia6
zaspanost
Dyskinesia
bradikardija podaljš intervala
for seizures were reported Neuroleptic malignant syndrome (see section 4.4) Dystonia (including oculogyration) Tardive dyskinesia Discontinuation symptoms7
prekatna
Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary hesitation Reproductive system and breast disorders
92
106 Priapism General disorders and administration site conditions Asthenia Fatigue Oedema Investigations Elevated plasma prolactin levels 8 1
koncentracije prolaktina 8
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
Klinič pomembno poveč telesne mase so opazili pri vseh izhodišnih indeksih telesne mase
107 In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
valproatom in olanzapinom povzroč nevtropenije pri 4, 1% bolnikov; mož vzroč dejavnik so
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
Med zdravljenjem z olanzapinom v kombinaciji z litijem ali ali divalproeksom se je 17, 4% bolnikov med akutnim zdravljenjem (do 6 tednov) poveč telesna masa, ala in sicer za > 7% od osnovne.